ArticleClinical drug investigation2018

Response to "Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database".

Rashid Kazerooni et al.PubMed ↗Publisher ↗

No numbers read from the abstract.